Literature DB >> 28298179

Preparation of peptide-MHC and T-cell receptor dextramers by biotinylated dextran doping.

Michael T Bethune1, Begoña Comin-Anduix2,3, Yu-Hsien Hwang Fu4, Antoni Ribas2,3,5, David Baltimore1.   

Abstract

Peptide-major histocompatibility complex (pMHC) multimers enable the detection, characterization, and isolation of antigen-specific T-cell subsets at the single-cell level via flow cytometry and fluorescence microscopy. These labeling reagents exploit a multivalent scaffold to increase the avidity of individually weak T-cell receptor (TCR)-pMHC interactions. Dextramers are an improvement over the original streptavidin-based tetramer technology because they are more multivalent, improving sensitivity for rare, low-avidity T cells, including self/tumor-reactive clones. However, commercial pMHC dextramers are expensive, and in-house production is very involved for a typical biology research laboratory. Here, we present a simple, inexpensive protocol for preparing pMHC dextramers by doping in biotinylated dextran during conventional tetramer preparation. We use these pMHC dextramers to identify patient-derived, tumor-reactive T cells. We apply the same dextran doping technique to prepare TCR dextramers and use these novel reagents to yield new insight into MHC I-mediated antigen presentation.

Entities:  

Keywords:  T-cell receptor (TCR); biotinylated dextran; cancer immunotherapy; dextramer; immunology; ligand discovery; major histocompatibility complex (MHC); multimer; pMHC; peptide; peptide-specific MHC clustering; tetramer; tumor antigen discovery

Mesh:

Substances:

Year:  2017        PMID: 28298179     DOI: 10.2144/000114525

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  6 in total

1.  Development of Cancer Immunotherapies.

Authors:  Diana C DeLucia; John K Lee
Journal:  Cancer Treat Res       Date:  2022

2.  γ9δ2T cell diversity and the receptor interface with tumor cells.

Authors:  Anna Vyborova; Dennis X Beringer; Domenico Fasci; Froso Karaiskaki; Eline van Diest; Lovro Kramer; Aram de Haas; Jasper Sanders; Anke Janssen; Trudy Straetemans; Daniel Olive; Jeanette Leusen; Lola Boutin; Steven Nedellec; Samantha L Schwartz; Michael J Wester; Keith A Lidke; Emmanuel Scotet; Diane S Lidke; Albert Jr Heck; Zsolt Sebestyen; Jürgen Kuball
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

3.  Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes.

Authors:  Marvin H Gee; Arnold Han; Shane M Lofgren; John F Beausang; Juan L Mendoza; Michael E Birnbaum; Michael T Bethune; Suzanne Fischer; Xinbo Yang; Raquel Gomez-Eerland; David B Bingham; Leah V Sibener; Ricardo A Fernandes; Andrew Velasco; David Baltimore; Ton N Schumacher; Purvesh Khatri; Stephen R Quake; Mark M Davis; K Christopher Garcia
Journal:  Cell       Date:  2017-12-21       Impact factor: 41.582

4.  Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules.

Authors:  Michael T Bethune; Xiao-Hua Li; Jiaji Yu; Jami McLaughlin; Donghui Cheng; Colleen Mathis; Blanca Homet Moreno; Katherine Woods; Ashley J Knights; Angel Garcia-Diaz; Stephanie Wong; Siwen Hu-Lieskovan; Cristina Puig-Saus; Jonathan Cebon; Antoni Ribas; Lili Yang; Owen N Witte; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-22       Impact factor: 11.205

5.  Enrichment and Quantification of Epitope-specific CD4+ T Lymphocytes using Ferromagnetic Iron-gold and Nickel Nanowires.

Authors:  Daniel E Shore; Thamotharampillai Dileepan; Jaime F Modiano; Marc K Jenkins; Bethanie J H Stadler
Journal:  Sci Rep       Date:  2018-10-24       Impact factor: 4.379

6.  Development of a T-cell receptor multimer with high avidity for detecting a naturally presented tumor-associated antigen on osteosarcoma cells.

Authors:  Kazue Watanabe; Tomohide Tsukahara; Shingo Toji; Shogo Saitoh; Yoshihiko Hirohashi; Munehide Nakatsugawa; Terufumi Kubo; Takayuki Kanaseki; Hidekazu Kameshima; Takeshi Terui; Noriyuki Sato; Toshihiko Torigoe
Journal:  Cancer Sci       Date:  2018-12-01       Impact factor: 6.716

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.